Kyverna Therapeutics, Inc.
KYTX$65M
Micro CapNASDAQBiological Products, (No Diagnostic Substances)🇺🇸North AmericaEMERYVILLE129 employees
Drugs in Pipeline
5
Phase 3 Programs
3
Upcoming Catalysts
5
Next Catalyst
Jun 30, 2026
10wMarket Overview
Stock performance and key metrics
KYTX News
Catalyst Timeline
5 upcoming, 3 past
Drug Pipeline
Standard lymphodepletion regimen
Lupus Nephritis
Standard of Care Treatment
Myasthenia Gravis
KYV-101
Systemic Sclerosis
KYV-101 anti-CD19 CAR-T cell therapy
Lupus Nephritis
Anti-CD20 mAB
Multiple Sclerosis, Primary Progressive
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Standard lymphodepletion regimen | Phase 3 | Lupus Nephritis | - | - |
Standard of Care Treatment | Phase 3 | Myasthenia Gravis | - | - |
KYV-101 | Phase 3 | Systemic Sclerosis | - | - |
KYV-101 anti-CD19 CAR-T cell therapy | Phase 2 | Lupus Nephritis | - | - |
Anti-CD20 mAB | Phase 2 | Multiple Sclerosis, Primary Progressive | - | - |
Regulatory Approvals
Data is aggregated from public sources (FDA, SEC, ClinicalTrials.gov). While we strive for accuracy, information may be incomplete, delayed, or contain errors. Terms apply